Grades of Fatty Liver on Ultrasound Explained

Grades of fatty liver on ultrasound (Grade 1, Grade 2 and Grade 3) describe how much fat has built up in the liver, detected by how brightly the organ reflects sound waves compared with the kidney. Fatty liver, or hepatic steatosis, is increasingly common in the UK and is closely linked to obesity, type 2 diabetes and alcohol intake. Understanding what each grade means, how fibrosis risk is assessed afterwards, and what steps you can take is essential for anyone who has received this finding on a scan report. This article explains the grading system clearly, using current NHS and NICE guidance.

What do the grades of fatty liver on ultrasound actually mean?

Ultrasound grades (1 to 3) categorise the degree of hepatic fat infiltration based on liver echogenicity, but do not measure fibrosis, inflammation or cirrhosis, which require separate tests.

The grades of fatty liver on ultrasound (Grade 1, Grade 2 and Grade 3) describe how much fat has accumulated within the liver, based on how the organ reflects sound waves during scanning. Fatty liver, also called hepatic steatosis, is defined histologically as fat droplets present in more than 5% of hepatocytes (liver cells); imaging-based definitions use validated thresholds that approximate this.^[2][14] Ultrasound grading gives clinicians a practical, non-invasive way to categorise the degree of fat infiltration and guide further investigation or management.

The grading system is widely used in NHS radiology departments and is reported alongside other findings such as liver size and texture. It is important to understand that these grades describe fat content only; they do not directly measure inflammation, fibrosis or cirrhosis, which require additional tests to assess. A higher grade does not automatically mean serious liver disease, but it does indicate a greater need for clinical review.

Fatty liver is increasingly common in the UK, closely linked to obesity, type 2 diabetes, high alcohol intake and metabolic syndrome. It can be broadly divided into metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease), alcohol-related liver disease (ALD), and an overlap category called MetALD, which applies where metabolic risk factors coexist with moderate alcohol intake. Understanding which category applies to you is an important part of the clinical assessment that follows an ultrasound finding.

Receiving a report mentioning fatty liver can feel alarming, but the grading system is a starting point for clinical decision-making rather than a final diagnosis. The sections below explain how the grades are determined, what each one means in practice, and what steps you can take in response.

How does an ultrasound scan detect and grade a fatty liver?

Ultrasound detects fatty liver by comparing liver brightness (echogenicity) with the kidney; fat-laden hepatocytes appear brighter, and grading also assesses vascular blurring, diaphragm visibility and deep attenuation.

Ultrasound detects fatty liver by measuring how brightly the liver reflects sound waves compared with the right kidney, a technique known as hepatorenal echogenicity comparison. Fat within liver cells (hepatocytes) causes the organ to appear brighter, or more echogenic, than normal on the ultrasound image. The greater the fat infiltration, the brighter and more uniform the liver appears, and the harder it becomes to see the deeper structures within it.

The sonographer or radiologist assesses several features during the scan:

• Echogenicity: How bright the liver appears relative to the kidney and spleen.

• Vascular blurring: Whether the walls of the portal and hepatic veins remain clearly visible.

• Diaphragm visibility: Whether the dome of the diaphragm can be seen through the liver tissue.

• Deep attenuation: Whether sound waves penetrate to the deeper parts of the liver or are absorbed before reaching them.

These features are combined to assign a grade. The process is subjective to some degree, meaning that results can vary between operators and machines, and there is no single universally standardised grading protocol across all NHS trusts. This is an acknowledged limitation of standard ultrasound grading, and it is one reason why additional investigations may be recommended when the clinical picture is unclear.

Ultrasound is generally considered reliable for detecting moderate to severe fatty liver but is less sensitive for mild steatosis (Grade 1), where fat content may be too low to produce a clearly abnormal image.^[8][9] It is also worth noting that a normal ultrasound does not exclude mild steatosis, particularly in people with obesity.^[8][9] Despite these limitations, ultrasound remains the first-line imaging tool in NHS practice because it is safe, widely available and does not involve radiation (NICE NG49).^[1][2]

Where greater precision is needed, some UK centres have access to quantitative techniques such as the controlled attenuation parameter (CAP) measured during FibroScan, or MRI-based proton density fat fraction (MRI-PDFF). These can quantify liver fat more accurately, though availability varies across the NHS.

What does each grade mean for your liver health and treatment?

Grade 1 indicates mild steatosis often manageable with lifestyle changes; Grade 2 and Grade 3 indicate progressively greater fat accumulation requiring blood tests, FIB-4 fibrosis scoring and possible specialist referral.

Each ultrasound grade of fatty liver carries different implications for liver health, and understanding them helps set realistic expectations about what further steps may be needed.

Grade 1 (Mild steatosis): The liver appears mildly brighter than the kidney, but the portal vein walls and diaphragm remain clearly visible. Fat infiltration is present but limited. At this stage, the liver is generally functioning normally, and lifestyle changes alone are often sufficient to reverse the finding. Routine monitoring and a review of metabolic risk factors (such as blood glucose, cholesterol and blood pressure) are typically recommended.

Grade 2 (Moderate steatosis): The liver is noticeably brighter, the portal vein walls become less distinct, and sound penetration begins to reduce. This grade suggests a more significant degree of fat accumulation. Clinicians will usually arrange blood tests including liver function tests (LFTs), a lipid profile, HbA1c and a platelet count to assess for underlying metabolic conditions and to enable fibrosis risk calculation (see below).

Grade 3 (Severe steatosis): The liver is markedly echogenic, the diaphragm is poorly seen or invisible, and deep structures are obscured by sound attenuation. This grade indicates substantial fat infiltration and warrants prompt clinical review.

It is important to understand that ultrasound grade does not equate to fibrosis stage. Fibrosis risk assessment is required for all patients with confirmed steatosis, regardless of grade. In UK primary care, the recommended first step is to calculate the FIB-4 score, which uses age, AST, ALT and platelet count. Age-adjusted cut-off values are used to interpret the result: a low FIB-4 score makes significant fibrosis unlikely, while an indeterminate or high score should prompt further testing with an enhanced liver fibrosis (ELF) blood test or FibroScan (transient elastography).^[1] Referral to hepatology is recommended where the FIB-4 or ELF result suggests high fibrosis risk, or where other concerning features are present (NICE NG49; BSG/BASL guidance).^[1]

Ultrasound grading also does not distinguish between simple steatosis and steatohepatitis (inflammation), which carries a higher risk of progression to fibrosis and cirrhosis. A clinician will interpret the grade alongside your full clinical history, alcohol intake, body weight and blood results to form a complete picture.

Can a fatty liver shown on ultrasound be reversed?

Fatty liver at all grades can improve or resolve with sustained lifestyle changes; a 5 to 10% reduction in body weight significantly reduces liver fat, and greater losses can resolve steatohepatitis in some patients.

Fatty liver, including Grade 2 and Grade 3 findings on ultrasound, can be reversed in many people through sustained lifestyle changes, particularly when significant fibrosis has not yet developed. The liver has a remarkable capacity for regeneration, and evidence shows that meaningful reductions in body weight, improvements in diet and increased physical activity can lead to measurable reductions in hepatic fat content.

The key evidence-based interventions recommended in UK clinical practice include:

• Weight reduction: A loss of 5 to 10% of body weight is associated with a significant reduction in liver fat.^[1][14] Losses of 10% or more have been shown in clinical studies to improve or resolve steatohepatitis in some patients (NICE NG49; EASL Clinical Practice Guidelines on MASLD).^[1][14]

• Dietary change: A Mediterranean-style diet, low in refined carbohydrates and saturated fat and rich in vegetables, wholegrains, fish and olive oil, is supported by evidence for reducing liver fat.

• Physical activity: Both aerobic exercise and resistance training have been shown to reduce hepatic steatosis independently of weight loss.^[16][17]

• Alcohol reduction or abstinence: For alcohol-related liver disease, reducing or stopping alcohol intake is the single most effective intervention.

• Management of metabolic conditions: Optimising blood glucose control in type 2 diabetes, treating dyslipidaemia and managing blood pressure all contribute to liver health.

For people with type 2 diabetes or obesity, certain medicines may also support liver fat reduction as part of a broader treatment plan. NICE guidance on weight management and type 2 diabetes outlines the clinical criteria for pharmacological treatment. There are currently no medicines specifically licensed in the UK for the treatment of MASLD itself, though research in this area is active and the licensing position may change over time.^[12][13]

Improvement is possible at all grades, including Grade 3, with effective and sustained intervention. However, at Grade 3 the priority is also to assess for and prevent progression to fibrosis, as the risk is greater. People with severe steatosis should not be discouraged from making lifestyle changes, as substantial improvements in liver fat have been demonstrated even at this stage.

When should you see a GP or specialist about your ultrasound results?

Contact your GP promptly after any fatty liver finding on ultrasound; Grade 2 or 3, abnormal liver function tests, hepatomegaly or mention of fibrosis all warrant priority review and FIB-4 calculation.

You should contact your GP promptly if you have received an ultrasound report showing any grade of fatty liver, particularly if you have not yet had a clinical review of the finding. A GP can interpret the result in the context of your full medical history, arrange relevant blood tests and decide whether onward referral is appropriate. Do not wait for symptoms to develop, as fatty liver disease is often silent in its early stages.

Contact your GP as a priority if your ultrasound report shows:

• Grade 2 or Grade 3 fatty liver, especially if you have not had recent liver function tests.

• Any mention of fibrosis, cirrhosis or an irregular liver surface, which require specialist assessment.

• An enlarged liver (hepatomegaly) noted alongside the steatosis finding.

• Abnormal liver function tests (raised ALT, AST, GGT, ALP or bilirubin) identified at the same time, as these may also indicate other liver conditions requiring evaluation.

Your GP should arrange baseline blood tests including LFTs, HbA1c, a lipid profile and a platelet count. These results allow calculation of the FIB-4 score, which is the recommended first-line tool for assessing fibrosis risk in primary care (NICE NG49). Depending on the FIB-4 result, your GP may arrange an ELF blood test or FibroScan, or refer you to a hepatologist or gastroenterologist for further assessment.

Seek urgent medical attention (call 999 or go to A&E) if you develop symptoms such as sudden severe abdominal pain, vomiting blood, passing black or tarry stools, or yellowing of the skin and eyes (jaundice) with confusion, as these may indicate serious liver complications requiring immediate assessment.

For non-urgent questions about your results or general advice on next steps, NHS 111 can provide guidance outside of GP hours.

For those managing weight as part of their liver health plan, Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where clinically appropriate options may be considered alongside lifestyle advice.

Scientific References

1. Metabolic dysfunction-associated steatotic liver disease (MASLD) [NG49].
2. Non-alcoholic fatty liver disease (NAFLD).
3. Validation of the new nomenclature of steatotic liver disease.
4. AGA Clinical Practice Update on the Evaluation and Management of Metabolic Dysfunction- and Alcohol-Associated Liver Disease: Expert Review.
5. Global epidemiological patterns and disease burden of MASLD, MetALD, and ALD.
6. Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023.
7. Comparative diagnostic performance of ultrasound-guided attenuation parameter versus B-mode scoring for hepatic steatosis assessment.
8. Strategy to Improve Diagnostic Performance of Hepatic Steatosis Grading Using Ultrasound: Combination of Qualitative and Quantitative Approaches.
9. Qualitative assessment of hepatic steatosis on modern grayscale ultrasound: more accurate than previously thought?.
10. Evaluation of Artificial Intelligence-Calculated Hepatorenal Index for Diagnosing Mild and Moderate Hepatic Steatosis in NAFLD.
11. Accuracy of controlled attenuation parameter (CAP) and MRI-PDFF for steatosis grading in metabolic associated fatty liver disease.
12. Draft scope – pharmacological treatment of MASLD/MASH [GID-TA11477].
13. Resmetirom (Rezdiffra) authorised to treat metabolic dysfunction-associated steatohepatitis (MASH) in adults.
14. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease.
15. Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis.
16. The effect of exercise training on intrahepatic triglyceride and hepatic insulin sensitivity: a systematic review and meta-analysis.
17. Exercise and ectopic fat in type 2 diabetes: A systematic review and meta-analysis.
18. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis.
19. Impact of weight loss and reduction of ultra-processed foods on liver fat content in MASLD: A randomized controlled trial.
20. A culturally adapted online Mediterranean diet intervention for MASLD (TIMA): study protocol for a randomized controlled trial.
21. Very low energy ketogenic diet vs. Mediterranean diet for MASLD: Superior steatosis reduction in a randomised pilot study.
22. MRI-based technologies for assessing non-alcoholic fatty liver disease – diagnostic tests consultation.

Frequently Asked Questions